Men of Color Continue To Be Underrepresented in Prostate Cancer Clinical Trials
Prostate cancer is the second most diagnosed cancer among men in the United States, and non-Hispanic black men bear a...
Progress Against Cancer
Prostate cancer is the second most diagnosed cancer among men in the United States, and non-Hispanic black men bear a...
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with...
Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method...
A new antihormone agent darolutamide (Nubeqa) provides men with nonmetastatic prostate cancer a third option to control the disease...
A recent study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression...
A new hormone therapy is the first treatment to be approved because it was found to markedly delay the...
Study: Urban native populations may have decreased survival following invasive prostate and breast cancer. Urban American Indians and Alaskan...
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts....
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Today